QQQ   305.08 (-0.09%)
AAPL   157.34 (+1.51%)
MSFT   271.04 (-3.00%)
META   197.11 (+0.77%)
GOOGL   101.05 (-0.56%)
AMZN   96.63 (-2.34%)
TSLA   183.01 (+1.60%)
NVDA   259.57 (+0.90%)
NIO   8.65 (+4.72%)
BABA   80.68 (-1.21%)
AMD   95.40 (-2.49%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.09 (+0.76%)
CGC   1.89 (-5.50%)
GE   90.12 (-0.19%)
DIS   93.83 (+0.68%)
AMC   4.25 (+1.67%)
PFE   40.56 (+1.15%)
PYPL   72.58 (-0.56%)
NFLX   304.39 (+0.29%)
QQQ   305.08 (-0.09%)
AAPL   157.34 (+1.51%)
MSFT   271.04 (-3.00%)
META   197.11 (+0.77%)
GOOGL   101.05 (-0.56%)
AMZN   96.63 (-2.34%)
TSLA   183.01 (+1.60%)
NVDA   259.57 (+0.90%)
NIO   8.65 (+4.72%)
BABA   80.68 (-1.21%)
AMD   95.40 (-2.49%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.09 (+0.76%)
CGC   1.89 (-5.50%)
GE   90.12 (-0.19%)
DIS   93.83 (+0.68%)
AMC   4.25 (+1.67%)
PFE   40.56 (+1.15%)
PYPL   72.58 (-0.56%)
NFLX   304.39 (+0.29%)
QQQ   305.08 (-0.09%)
AAPL   157.34 (+1.51%)
MSFT   271.04 (-3.00%)
META   197.11 (+0.77%)
GOOGL   101.05 (-0.56%)
AMZN   96.63 (-2.34%)
TSLA   183.01 (+1.60%)
NVDA   259.57 (+0.90%)
NIO   8.65 (+4.72%)
BABA   80.68 (-1.21%)
AMD   95.40 (-2.49%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.09 (+0.76%)
CGC   1.89 (-5.50%)
GE   90.12 (-0.19%)
DIS   93.83 (+0.68%)
AMC   4.25 (+1.67%)
PFE   40.56 (+1.15%)
PYPL   72.58 (-0.56%)
NFLX   304.39 (+0.29%)
QQQ   305.08 (-0.09%)
AAPL   157.34 (+1.51%)
MSFT   271.04 (-3.00%)
META   197.11 (+0.77%)
GOOGL   101.05 (-0.56%)
AMZN   96.63 (-2.34%)
TSLA   183.01 (+1.60%)
NVDA   259.57 (+0.90%)
NIO   8.65 (+4.72%)
BABA   80.68 (-1.21%)
AMD   95.40 (-2.49%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.09 (+0.76%)
CGC   1.89 (-5.50%)
GE   90.12 (-0.19%)
DIS   93.83 (+0.68%)
AMC   4.25 (+1.67%)
PFE   40.56 (+1.15%)
PYPL   72.58 (-0.56%)
NFLX   304.39 (+0.29%)
OTCMKTS:ASPCF

Acerus Pharmaceuticals - ASPCF Stock Forecast, Price & News

$0.22
0.00 (0.00%)
(As of 03/17/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.22
▼
$0.22
50-Day Range
$0.22
▼
$0.37
52-Week Range
$0.22
▼
$8.16
Volume
N/A
Average Volume
1,500 shs
Market Capitalization
$1.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ASPCF stock logo

About Acerus Pharmaceuticals (OTCMKTS:ASPCF) Stock

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Stock News Headlines

March 14, 2023 | finance.yahoo.com
Acerus Announces Commencement of Court-Approved Sale and Investment Solicitation Process
January 16, 2023 | theglobeandmail.com
Acerus Pharmaceuticals: Top 10 Undervalued Nano Cap Stocks on TSX (ASP)
March 20, 2023 | Investing Daily (Ad)
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
November 15, 2022 | finance.yahoo.com
Acerus Reports Third Quarter 2022 Financial Results
October 3, 2022 | finance.yahoo.com
Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders
September 21, 2022 | marketwatch.com
Acerus Pharmaceuticals to Initiate Strategic Review of Operations
September 21, 2022 | finance.yahoo.com
Acerus Announces Initiation of Strategic Review
August 23, 2022 | seekingalpha.com
Acerus Pharmaceuticals CFO resigns effective November 20, 2022
March 20, 2023 | Investing Daily (Ad)
Check Out This 6-Year Win Streak
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
August 14, 2022 | seekingalpha.com
Acerus Pharmaceuticals Corporation (ASPCF) CEO Edward Gudaitis on Q2 2022 Results - Earnings Call Transcript
August 5, 2022 | finance.yahoo.com
Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders
June 27, 2022 | finance.yahoo.com
Acerus Announces Voting Results for the 2022 Annual Meeting
June 24, 2022 | seekingalpha.com
Acerus Pharmaceuticals increases loan facility to $37.94M
May 11, 2022 | seekingalpha.com
Acerus Pharmaceuticals GAAP EPS of $0.00, revenue of $0.78M
May 5, 2022 | finance.yahoo.com
Acerus To Report Q1-2022 Financial Results And Host Investor Call
April 26, 2022 | finance.yahoo.com
Acerus Announces Completion of Share Consolidation
April 19, 2022 | finance.yahoo.com
Acerus Announces Share Consolidation
February 28, 2022 | seekingalpha.com
Acerus to acquire Florida-based Serenity in cash/stock deal
February 28, 2022 | finance.yahoo.com
Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™
See More Headlines
Receive ASPCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASPCF Company Calendar

Today
3/20/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ASPCF
CUSIP
N/A
CIK
N/A
Web
www.aceruspharma.com
Phone
(416) 679-0771
Fax
905-569-1809
Employees
14
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,820,000.00
Net Margins
-924.33%
Pretax Margin
-924.33%
Return on Equity
N/A
Return on Assets
-74.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.67
Quick Ratio
0.34

Sales & Book Value

Annual Sales
$2.12 million
Price / Sales
0.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.38) per share
Price / Book
-0.07

Miscellaneous

Outstanding Shares
7,708,000
Free Float
N/A
Market Cap
$1.69 million
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Edward Gudaitis
    President, CEO & Non-Independent Director
  • Naveed Manzoor
    Chief Financial Officer
  • Christopher Sorli
    Chief Medical Officer
  • Philippe Savard
    Secretary, Senior Vice President & General Counsel
  • Chris Witty
    Investor Relations Contact

Key Competitors

View All Competitors













ASPCF Stock - Frequently Asked Questions

How have ASPCF shares performed in 2023?

Acerus Pharmaceuticals' stock was trading at $0.5579 at the beginning of 2023. Since then, ASPCF shares have decreased by 60.6% and is now trading at $0.2199.
View the best growth stocks for 2023 here.

When did Acerus Pharmaceuticals' stock split?

Acerus Pharmaceuticals's stock reverse split on the morning of Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASPCF stock can currently be purchased for approximately $0.22.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals (OTCMKTS:ASPCF) has a market capitalization of $1.69 million and generates $2.12 million in revenue each year. The company earns $-33,820,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for the company is www.aceruspharma.com. The company can be reached via phone at (416) 679-0771, via email at ir@aceruspharma.com, or via fax at 905-569-1809.

This page (OTCMKTS:ASPCF) was last updated on 3/20/2023 by MarketBeat.com Staff